J&J Receives CE Mark Approvals for Cereglide Aspiration Devices for Stroke Treatment

June 2, 2026—Johnson & Johnson (J&J) announced it has received CE Mark approvals for its Cereglide 42 and Cereglide 57 aspiration catheters. The devices are single-lumen, variable-stiffness catheter with a hydrophilic coating to improve lubricity during navigation and a radiopaque marker at the distal tip to enable fluoroscopic visualization.

Additionally, CE Mark approval was granted for the company’s Cereglide 71 aspiration system, composed of the Cereglide 71 aspiration catheter and Innerglide 7 delivery aid, to treat selected neurovascular vessels. The Innerglide 7 delivery aid is a single-lumen catheter with a tapered tip, hydrophilic coating for increased lubricity, a radiopaque tip for fluoroscopic visualization, and a proximal luer hub. The Innerglide 7 delivery aid is designed to facilitate delivery of the Cereglide 71 catheter to select neurovascular vessels. The Cereglide 71 aspiration catheter was initially launched in Europe in April 2024.

The additions expand the stroke solutions portfolio of J&J MedTech in the Europe, Middle East, and Asia markets, noted the press release.

J&J stated that the Cereglide family of catheters now includes the 42, 57, 71, and 92 aspiration catheters to provide a range of sizes to support aspiration during mechanical thrombectomy and promote procedural consistency and device compatibility.

In February 2026, the company announced the United States launch of the Cereglide 42 and Cereglide 57 aspiration catheters and the Innerglide 7 delivery aid as part of its aspiration-first stroke portfolio.